Singapore's S*BIO Shutters Discovery Operations To Focus On Finding Partners For Lead JAK2 Inhibitor, Interim CEO Says
This article was originally published in PharmAsia News
Executive Summary
Dispelling rumors that S*BIO is on the sales block, interim CEO Tamar Howson told PharmAsia News that the company is refocusing its efforts from being a discovery-oriented biotech company to commercializing its late-stage products
You may also be interested in...
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
Onyx Walks Away From Option To Develop S*BIO JAK2 Inhibitors; S*BIO CEO Looks To Chart A New Course
Although anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.